Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a multicenter, blinded evaluator, randomized, prospective, no treatment control clinical study to identify whether RHA® Redensity Eye (*) is superior to no treatment for the correction of moderate to severe tissue volume deficiencies in the infraorbital regions.
The study will include at least 20% of subjects with Fitzpatrick skin types IV-VI.
The Treating Investigator (TI) and the Blinded Live Evaluator (BLE) will evaluate the subject's infraorbital hollows independently of each other using the Teoxane Infraorbital Hollows Scale (TIOHS) at Screening (Visit 1) for eligibility.
If the subject is eligible, the BLE's assessment will be used for the Baseline of the primary endpoint.
Enrolled subjects will be randomly assigned in a ratio of 3:1 at Screening (Visit 1) to receive RHA® Redensity Eye or to receive no treatment (No-treatment control group).
Subjects receiving RHA® Redensity Eye will be further divided by the method of administration (i.e. injection with a 30G ½" needle or 25G 1 ½" cannula), which will be defined for each site at the beginning of the study. Site selection will aim to achieve approximately 1:1 distribution between the administration method subgroups. The BLE will be blinded to the study groups (RHA® Redensity Eye group or No treatment control group).
For subjects randomly assigned to RHA® Redensity Eye group, the study will be conducted in 2 Phases - Phase 1a and Phase 2.
For subjects randomly assigned to No-treatment control group, the study will be conducted in 3 Phases - Phase 1a, Phase 1b and Phase 2.
The Phase 1b is not applicable for the subject assigned to the RHA® Redensity Eye group.
(*): TEO-RHA-1902 was conducted with RHA® Redensity Eye Lido, that contains Lidocaine.
Phase 1a:
Subjects who will be randomly assigned to the RHA® Redensity Eye group at Screening will receive their injection at Visit 1. Subjects will come to the site 12 weeks (primary endpoint) after the initial treatment. Afterwards, subjects will proceed directly to Phase 2.
Subjects randomly assigned to the No-treatment control group at Screening will receive no treatment in Phase 1a of the study. They will come to the site 12 weeks (primary endpoint) after randomization. After completing all assessments, subjects will immediately begin Phase 1b (Visit 1b is on the same day as Visit at Week 12) and will receive their initial treatment with RHA® Redensity Eye.
Phase 1b:
Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Once all evaluations applicable for Visit at Week 12 are completed, subjects will proceed directly to Visit 1b (on the same day). Evaluations completed at Week 12 will be used for Visit 1b and will become the new Baseline for Phase 1b.
Subjects will receive their initial treatment with RHA® Redensity Eye at Visit 1b.
Subjects will follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye will be administered on the same day (Visit 1b). Subjects will come to the site 12 weeks after their initial treatment. Afterwards, subjects will proceed to Phase 2.
Phase 2 and Exit visit:
Phase 2 will occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group (after Phase 1b).
All these subjects will come to the site 24 weeks, and 52 weeks after their initial treatment. All subjects will be followed for 52 weeks after their initial treatment with RHA® Redensity Eye.
Subjects will be offered retreatment (52 weeks after their initial treatment). Retreatment will be administered if the TI deems it to be appropriate and the subject agrees. If the subject does not receive retreatment, Visit at 52 weeks after initial treatment will become the Exit visit.
If the subject receives retreatment, the subjects will come to the site 12 weeks after retreatment for follow-up and safety assessments. This will be the Exit visit.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RHA® Redensity Eye Group | Experimental | RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. |
|
| No-Treatment Control First, Then RHA Redensity Eye Treatment Group | No Intervention | During Phase 1a, participants from No-treatment control group do not receive treatment. Primary endpoint assessments are done at Week 12. Once all evaluations applicable for Primary Endpoint at Week 12 are completed, subjects proceed directly to Phase 1b (on the same day). Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Phase 1b: Subjects receive their initial treatment with RHA® Redensity Eye at Visit 1b. Subjects follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye is administered on the same day (Visit 1b). Subjects come to the site 12 weeks after their initial treatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RHA® Redensity Eye | Device | A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| Measure | Description | Time Frame |
|---|---|---|
| Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1a | The TIOHS is a validated 5-point scale for assessing Infra-orbital hollows severity. Possible scores range from 0 (Absent) to 4 (Very Severe). Change = (Week 12 - Baseline score). A TIOHS change of 1-grade will be considered clinically significant. Phase 1a: Subjects are randomly assigned to the RHA® Redensity Eye group or to the to the No-treatment control group, and come to the site 12 weeks (primary endpoint) after randomization. | Period 1 - Phase 1a: Week 12 after last treatment |
| The Modified FACE-Q "Appearance of Lower Eyelids" Change From Baseline Score for Subjects Treated With RHA® Redensity at Week 12 After Last Treatment - Phase 1a | The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective. The modified FACE-Q questionnaire is composed of 4 questions with a score linked to answers (1 being "Not at all" and 4 being "Extremely"). To calculate the FACE-Q score, outcomes from all 4 questions were pooled, data were transformed so that higher scores reflected a superior (positive) outcome, and adapted to a scale of 100 units (i.e. worst/lowest score = 0, best/highest score = 100). Phase 1a: Subjects are randomly assigned to the RHA® Redensity Eye group or to the to the No-treatment control group, and come to the site 12 weeks (primary endpoint) after randomization. | Period 1 - Phase 1a: Change from Baseline at Week 12 after last treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects Who Scored Themselves Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Subject at Weeks 12, 24, 52 After Last Treatment and at Week 12 After Retreatment - Phase 2 | The Global Aesthetic Improvement (GAI) is a subjective, balanced, 5-point dynamic scale assessing cosmetic improvement. Possible scores range from "much improved", "improved", "no change", "worse", to "much worse". The GAI will be assessed using the pre-injection baseline photograph. Phase 3 - Phase 2: Subjects from No-Treatment group receive their treatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| United States, California | Encino | California | 91436 | United States | ||
| United States, Santa Monica |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | RHA Redensity Eye Group | Phase 1a RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| FG001 | No-Treatment Control First, Then RHA Redensity Eye Treatment Group | During Phase 1a, participants from No-treatment control group do not receive treatment. Primary endpoint assessments are done at Week 12. Once all evaluations applicable for Primary Endpoint at Week 12 are completed, subjects proceed directly to Phase 1b (on the same day). Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Phase 1b: Subjects receive their initial treatment with RHA® Redensity Eye at Visit 1b. Subjects follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye is administered on the same day (Visit 1b). Subjects come to the site 12 weeks after their initial treatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| FG002 | Pooled Safety Assessment: All Participants | Phases 1a, 1b and 2 Pooled data (i.e., after the No-Treatment group received RHA® Redensity Eye after primary endpoint at Week 12, data from both treatment groups were pooled) were used to assess the overall safety of RHA® Redensity Eye as well as effectiveness of RHA® Redensity Eye over time up to 52 weeks after treatment and 12 weeks following retreatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period 1: Phase 1a |
| |||||||||||||||||||
| Period 2: Phase 1b |
| |||||||||||||||||||
| Period 3: Phase 2 |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | RHA Redensity Eye Group | Phase 1a RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Week 12 After Last Treatment, Using the TIOHS - Phase 1a | The TIOHS is a validated 5-point scale for assessing Infra-orbital hollows severity. Possible scores range from 0 (Absent) to 4 (Very Severe). Change = (Week 12 - Baseline score). A TIOHS change of 1-grade will be considered clinically significant. Phase 1a: Subjects are randomly assigned to the RHA® Redensity Eye group or to the to the No-treatment control group, and come to the site 12 weeks (primary endpoint) after randomization. | Period 1: Phase 1a - Primary endpoint on the ITT population | Posted | Number | percentage of responders | Period 1 - Phase 1a: Week 12 after last treatment |
|
52 to 64 (for patients receiving re-treatment) weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | RHA Redensity Eye Group | Phase 1a RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cholecystitis Acute | Hepatobiliary disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Injection Site Discolouration | General disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Research Scientist | TEOXANE SA | +41(0) 22 344 96 36 | clinical@teoxane.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Apr 24, 2024 | Oct 2, 2025 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 24, 2024 | Oct 2, 2025 | SAP_001.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. |
| Number of Subjects Scored Themselves Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Blinded Live Evaluator (BLE) at Weeks 12, 24, 52 After Last Treatment and at Week 12 After Retreatment - Phase 2 | The Global Aesthetic Improvement (GAI) is a subjective, balanced, 5-point dynamic scale assessing cosmetic improvement. Possible scores range from "much improved", "improved", "no change", "worse", to "much worse". The GAI will be assessed using the pre-injection baseline photograph. Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3 - Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. |
| Number of Subjects "Satisfied" or "Very Satisfied" With Study Treatment Using the Subject Satisfaction Scale at Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment - Phase 2 | The Subject Satisfaction Scale is a subjective, balanced, 5-point scale assessing subject satisfaction with study treatment. Possible scores range from with 1 (very satisfied) to 5 (very dissatisfied). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
| Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment Using the TIOHS - Phase 2 | The TIOHS is a validated 5-point scale for assessing Infra-orbital hollows severity. Possible scores range from 0 (Absent) to 4 (Very Severe). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
| Subject's Perception of Treatment Effectiveness as Per the "Appearance of Lower Eyelids " FACE-Q Scale Questionnaire at Baseline, Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment - Phase 2 | The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective. The FACE-Q questionnaire is composed of 7 questions with a score linked to answers (1 being "Not at all" and 4 being "Extremely"). To calculate the FACE-Q score, outcomes from all 7 questions were pooled, data were transformed so that higher scores reflected a superior (positive) outcome, and adapted to a scale of 100 units (i.e. worst/lowest score = 0, best/highest score = 100). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3: Phase 2 - ITT population - Change from Baseline at Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
| Santa Monica |
| California |
| 90212 |
| United States |
| United States, Florida | Coral Gables | Florida | 33146 | United States |
| United States, Illinois | Chicago | Illinois | 60611 | United States |
| PP Population |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| PP Population |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| BG001 | No-Treatment Control First, Then RHA Redensity Eye Treatment Group | During Phase 1a, participants from No-treatment control group do not receive treatment. Primary endpoint assessments are done at Week 12. Once all evaluations applicable for Primary Endpoint at Week 12 are completed, subjects proceed directly to Phase 1b (on the same day). Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Phase 1b: Subjects receive their initial treatment with RHA® Redensity Eye at Visit 1b. Subjects follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye is administered on the same day (Visit 1b). Subjects come to the site 12 weeks after their initial treatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Fitzpatrick Skin Type | Fitzpatrick skin type as determined by the Treating Investigator on the skin tone scale developed to classify skin coloring and response to ultraviolet (UV) radiation. The scale contains 6 grades: I: Pale white skin; Always burns, does not tan. II: Fair skin; Burns easily, tans poorly. III: Darker white skin; Tans after initial burn. IV: Light brown skin; Burns minimally, tans easily. V: Brown skin; Rarely burns, tans darkly easily. VI: Dark brown or black skin; Never burns, always tans darkly. | Count of Participants | Participants |
|
| OG001 | No-Treatment Control First, Then RHA Redensity Eye Treatment Group | During Phase 1a, participants from No-treatment control group do not receive treatment. Primary endpoint assessments are done at Week 12. Once all evaluations applicable for Primary Endpoint at Week 12 are completed, subjects proceed directly to Phase 1b (on the same day). Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Phase 1b: Subjects receive their initial treatment with RHA® Redensity Eye at Visit 1b. Subjects follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye is administered on the same day (Visit 1b). Subjects come to the site 12 weeks after their initial treatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. |
|
|
| Primary | The Modified FACE-Q "Appearance of Lower Eyelids" Change From Baseline Score for Subjects Treated With RHA® Redensity at Week 12 After Last Treatment - Phase 1a | The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective. The modified FACE-Q questionnaire is composed of 4 questions with a score linked to answers (1 being "Not at all" and 4 being "Extremely"). To calculate the FACE-Q score, outcomes from all 4 questions were pooled, data were transformed so that higher scores reflected a superior (positive) outcome, and adapted to a scale of 100 units (i.e. worst/lowest score = 0, best/highest score = 100). Phase 1a: Subjects are randomly assigned to the RHA® Redensity Eye group or to the to the No-treatment control group, and come to the site 12 weeks (primary endpoint) after randomization. | Period 1 -ITT Population | Posted | Mean | Standard Deviation | score on a scale | Period 1 - Phase 1a: Change from Baseline at Week 12 after last treatment |
|
|
|
| Secondary | Number of Subjects Who Scored Themselves Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Subject at Weeks 12, 24, 52 After Last Treatment and at Week 12 After Retreatment - Phase 2 | The Global Aesthetic Improvement (GAI) is a subjective, balanced, 5-point dynamic scale assessing cosmetic improvement. Possible scores range from "much improved", "improved", "no change", "worse", to "much worse". The GAI will be assessed using the pre-injection baseline photograph. Phase 3 - Phase 2: Subjects from No-Treatment group receive their treatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. | Posted | Count of Participants | Participants | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. |
|
|
|
| Secondary | Number of Subjects Scored Themselves Either "Much Improved" or "Improved" on Global Aesthetic Improvement (GAI) Scale by the Blinded Live Evaluator (BLE) at Weeks 12, 24, 52 After Last Treatment and at Week 12 After Retreatment - Phase 2 | The Global Aesthetic Improvement (GAI) is a subjective, balanced, 5-point dynamic scale assessing cosmetic improvement. Possible scores range from "much improved", "improved", "no change", "worse", to "much worse". The GAI will be assessed using the pre-injection baseline photograph. Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3 -Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. | Posted | Count of Participants | Participants | Period 3 - Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. |
|
|
|
| Secondary | Number of Subjects "Satisfied" or "Very Satisfied" With Study Treatment Using the Subject Satisfaction Scale at Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment - Phase 2 | The Subject Satisfaction Scale is a subjective, balanced, 5-point scale assessing subject satisfaction with study treatment. Possible scores range from with 1 (very satisfied) to 5 (very dissatisfied). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3 - Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. | Posted | Count of Participants | Participants | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
|
|
|
| Secondary | Change of 1 Point From Baseline in Infra-Orbital Hollows Severity Rated by the Blinded Live Evaluator (BLE) at Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment Using the TIOHS - Phase 2 | The TIOHS is a validated 5-point scale for assessing Infra-orbital hollows severity. Possible scores range from 0 (Absent) to 4 (Very Severe). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. | Posted | Count of Participants | Participants | Period 3: Phase 2 - ITT population - Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
|
|
|
| Secondary | Subject's Perception of Treatment Effectiveness as Per the "Appearance of Lower Eyelids " FACE-Q Scale Questionnaire at Baseline, Weeks 12, 24, 52 After Initial Treatment and at Week 12 After Retreatment - Phase 2 | The FACE-Q measures the experience and outcomes of aesthetic facial procedures from the patient's perspective. The FACE-Q questionnaire is composed of 7 questions with a score linked to answers (1 being "Not at all" and 4 being "Extremely"). To calculate the FACE-Q score, outcomes from all 7 questions were pooled, data were transformed so that higher scores reflected a superior (positive) outcome, and adapted to a scale of 100 units (i.e. worst/lowest score = 0, best/highest score = 100). Period 3 - Phase 2: Subjects from No-Treatment group receive their teatment with RHA® Redensity Eye following primary endpoint assessment, and enter into Phase 2. Phase 2 occur 12 weeks after receiving initial treatment with RHA® Redensity Eye for subjects in the RHA® Redensity Eye group and the No-treatment control group, data are pooled for analysis. | Period 3:Phase 2 - ITT population - Weeks 12, 24, 52 after last treatment and at Week 12 after retreatment. | Posted | Mean | Standard Deviation | score on a scale | Period 3: Phase 2 - ITT population - Change from Baseline at Weeks 12, 24, 52 after initial treatment and at Week 12 after retreatment. |
|
|
|
| 0 |
| 183 |
| 0 |
| 183 |
| 28 |
| 183 |
| EG001 | No-Treatment Control First, Then RHA Redensity Eye Treatment Group | During Phase 1a, participants from No-treatment control group do not receive treatment. Primary endpoint assessments are done at Week 12. Once all evaluations applicable for Primary Endpoint at Week 12 are completed, subjects proceed directly to Phase 1b (on the same day). Phase 1b is only applicable to subjects initially randomly assigned to the No-treatment control group. Phase 1b: Subjects receive their initial treatment with RHA® Redensity Eye at Visit 1b. Subjects follow the same schedule as those initially randomly assigned to the RHA® Redensity Eye group: RHA® Redensity Eye is administered on the same day (Visit 1b). Subjects come to the site 12 weeks after their initial treatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. | 0 | 65 | 0 | 65 | 0 | 65 |
| EG002 | Pooled Safety Assessment | Phases 1a, 1b and 2 Pooled data (i.e., after the No-Treatment group received RHA® Redensity Eye after primary endpoint at Week 12, data from both treatment groups were pooled) were used to assess the overall safety of RHA® Redensity Eye as well as effectiveness of RHA® Redensity Eye over time up to 52 weeks after treatment and 12 weeks following retreatment. RHA® Redensity Eye is injected from the sub-dermis to the periosteum in the infraorbital hollow. Up to 1.0 mL per eye at each treatment (max: 2.0 mL per treatment). No touch-up treatment provided. RHA® Redensity Eye: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer. For the pooled population, of the 65 subjects in the No-Treatment group, 13 did not reach Week 12 to crossover and receive RHA Redensity® Eye Lido treatment and 2 of the 50 who reached Week 12 did not receive treatment at that visit. Therefore, there were 233 subjects as part of SAFT for the pooled data set | 0 | 233 | 2 | 233 | 30 | 233 |
| Cellulitis | Infections and infestations | Systematic Assessment |
|
| Injection Site Mass | General disorders | Systematic Assessment |
|
| Injection Site Swelling | General disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
Not provided
|
| Week 52 after last treatment |
|
|
| Week 12 after retreatment |
|
|
|
| Week 52 after last treatment |
|
|
| Week 12 after retreatment |
|
|
|
| Week 52 after last treatment |
|
|
| Week 12 after retreatment |
|
|
|
| Week 52 after last treatment |
|
|
| Week 12 after retreatment |
|
|
|
| Week 52 after last treatment |
|
|
| Week 12 after retreatment |
|
|